NEOS Investment Management LLC Sells 6,331 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

NEOS Investment Management LLC lessened its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 23.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 20,261 shares of the biopharmaceutical company’s stock after selling 6,331 shares during the period. NEOS Investment Management LLC’s holdings in Celldex Therapeutics were worth $512,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. EverSource Wealth Advisors LLC raised its position in Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 878 shares during the period. KBC Group NV raised its holdings in Celldex Therapeutics by 79.1% in the 4th quarter. KBC Group NV now owns 3,728 shares of the biopharmaceutical company’s stock worth $94,000 after purchasing an additional 1,647 shares during the period. AlphaQuest LLC grew its holdings in Celldex Therapeutics by 171.0% during the fourth quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 2,705 shares during the period. E Fund Management Co. Ltd. purchased a new stake in Celldex Therapeutics in the fourth quarter worth about $273,000. Finally, KLP Kapitalforvaltning AS purchased a new stake in Celldex Therapeutics in the fourth quarter worth about $306,000.

Celldex Therapeutics Stock Down 0.3 %

Shares of CLDX stock opened at $19.93 on Monday. The stock has a market cap of $1.32 billion, a P/E ratio of -7.75 and a beta of 1.76. The company’s fifty day simple moving average is $21.90 and its two-hundred day simple moving average is $26.23. Celldex Therapeutics, Inc. has a 52 week low of $18.61 and a 52 week high of $47.00.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.02. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. On average, analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. UBS Group assumed coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They set a “buy” rating and a $44.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a report on Friday, February 28th. Morgan Stanley assumed coverage on shares of Celldex Therapeutics in a research report on Thursday, March 20th. They set an “overweight” rating and a $46.00 price objective on the stock. The Goldman Sachs Group lowered their target price on shares of Celldex Therapeutics from $42.00 to $36.00 and set a “neutral” rating on the stock in a research note on Monday, March 3rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $54.33.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.